Oxford Nanopore Technolo... Share Discussion Threads

[mirabeau] 16/9/2024 07:41

flying again

[bamboo2] 16/9/2024 07:40

Boston calling 2024
Monday 16th - Tuesday 17 September 2024

Maybe a few technical announcements over the next day or two.
Follow Nanopore on twitter for updates.

[brucie5] 16/9/2024 07:18

Morning campers.

[bamboo2] 14/9/2024 19:06

Tricky, read the full article for context.
There's a token on the link.

[brucie5] 14/9/2024 17:58

Let's get back 2.50 first.

[trickydicky1] 14/9/2024 13:07

“certainly is interesting … if somebody came in and made an offer”

Why is that interesting? Do your employees actually want to work for someone else? Do your shareholders not want to hold on to a business at an inflexion point? How would your customers, and NOVO in particular view this?

Curious! Is demonstrating the share price is ‘wrong’ interesting? Why?

[bamboo2] 14/9/2024 10:39

Gordon Sanghera: ‘I thought I’d have the tenure of a Premier League manager’




"Reforms by the Financial Conduct Authority designed to make London a more attractive listing destination, also mean that the company is set to join the FTSE 250 mid-cap index.

A share structure introduced at the time of the float, whereby Sanghera was handed a so-called limited anti-takeover share, giving him rights for three years to block hostile takeover approaches, meant it was ineligible for a premium listing, preventing it from joining the FTSE indices.

Inclusion will bring “much-needed liquidity” to its shares, he thinks, and while the anti-takeover share is due to lapse next month, potentially leaving Oxford Nanopore in play, he’s relaxed.

“It certainly is interesting … if somebody came in and made an offer and it was a premium that shows that maybe the share price is wrong.”"

[bamboo2] 13/9/2024 17:20

Re 1631, On Twitter, over the past two days, Jeff Nivala's post describing an approach for single-molecule protein reading using Nanopore has reached 68,700 views!

[brucie5] 13/9/2024 15:49

Bullish close above 6 month high. I imagine this will now be on the radar of traders like Michael Taylor?

[brucie5] 13/9/2024 10:15

Appreciate your work keeping us up to date Bamboo. If momentum seems to have stalled on the share price the good news is that longer it stays above the 200sma the nearer we are to the confirmation of a 50/100/200 sma crossover, which at this rate should be with us in time for October. Meantime, am I right in thinking that Novo have more shares to buy on the open market?

[bamboo2] 12/9/2024 19:31

Bring streamlined genomics into your lab with ElysION — the sample-to-answer automated sequencing solution. ElysION is the go-to choice for users seeking a hands-free, simplified genomic workflow that goes from sample to data analysis.

Jonathon Edgeworth discusses the latest sample to answer sequencer from ONT.



[139 views 10 Sept 2024]

[bamboo2] 11/9/2024 20:54

Breakthrough towards protein sequencing using Oxford Nanopore holds promise for disease research and drug development





New protein sequencing ‘proof-of-concept' method published in Nature shows promise in sequencing long, intact protein strands at single molecule resolution.

In a research collaboration with Oxford Nanopore Technologies, scientists from the University of Washington have unveiled a groundbreaking ‘proof-of-concept’ method showcasing the capability of the Oxford Nanopore sensing platform to read single protein molecules, a major step forward in protein analysis. In a study published today in Nature, the innovative technique enables researchers to read long, intact polypeptide strands, offering new possibilities for understanding complex biological processes and diseases.

Proteins are the molecular machines that drive nearly all functions in living organisms, from muscle movement to immune response. Proteins can exist in many different forms, known as proteoforms, which are created through slight variations such as mutations or post-translational modifications. These subtle changes can have a profound impact not only on protein function but also on disease development, including cancer, Alzheimer's, and autoimmune disorders. Although understanding these variations in full-length proteins is critical for deciphering their roles in health and disease, a protein’s complex structure has so far made it difficult to analyse at single molecule resolution.

Oxford Nanopore ribosome

In a new study, 'Multi-pass, single-molecule nanopore reading of long protein strands', a research team at the University of Washington, led by Jeff Nivala, showcased an innovative approach using a protein unfoldase, ClpX, in combination with Oxford Nanopore’s sensing platform, to enable the individual protein molecules to pass through the nanopore while generating a readable signal. The method allows scientists to 'unzip' and read the protein one amino acid at a time— analogous to nanopore DNA sequencing, but now applied to proteins. Crucially, this method also enables researchers to reread the same protein strand multiple times, boosting the accuracy of the results and making it easier to detect small but significant differences between proteoforms.

'This study highlights the remarkable versatility of the Oxford Nanopore sensing platform,' said Lakmal Jayasinghe, SVP of R&D Biologics at Oxford Nanopore Technologies. 'Beyond its established use in sequencing DNA and RNA, the platform can now be adapted for novel applications such as protein sequencing. With its distinctive features including portability, affordability, and real-time data analysis, researchers can delve into proteomics at an unprecedented level by performing sequencing of entire proteins using the nanopore platform. Exciting developments lie ahead for the field of proteomics with this groundbreaking advancement.'

This method represents ‘proof of concept’ that will require further R&D before broader clinical application, however the implications of accurately identifying and characterising full-length proteins are significant, creating potential opportunities to uncover new protein markers for disease and guide the development of targeted drugs. It also opens up new possibilities in precision medicine, where in the future treatments could be tailored based on an individual’s unique protein profile.

'This technology integrates many of the essential features required to develop a transformative approach to protein sequencing,' said Nivala, faculty and co-director of the Molecular Information Systems Lab in the UW’s Paul G. Allen School of Computer Science & Engineering. 'It could lead to groundbreaking applications in disease characterization, drug discovery, and the study of cellular processes, offering a level of detail previously unattainable.'

In addition to its potential clinical applications, the technology could also be applied to the development of protein-based barcoding systems, allowing researchers to create libraries of protein sequences for use in advanced diagnostics, therapeutic monitoring, and more.

[bamboo2] 10/9/2024 15:39

Oxford Nanopore Technologies to Sue BGI Group Affiliates for Contract Breach Sep 10, 2024

Use link for complete article [or search for it on twitter]


NEW YORK – Oxford Nanopore Technologies disclosed Tuesday that it has filed an ex parte application in the US District Court for the Northern District of California to serve subpoenas on Complete Genomics, Innomics (formerly known as BGI Americas), MGI Americas, and other entities to support a lawsuit that it intends to file in the courts of England and Wales.

According to a regulatory filing, Oxford Nanopore said it plans to sue BGI Tech Solutions, BGI Group, BGI, Beijing Genomics Institute at Shenzhen, MGI Holdings, and MGI Tech in England for breach of contractual obligations, common law obligations of confidence, and duties under the Trade Secrets Regulations 2018. Oxford Nanopore also said it will file an entitlement claim to a license of certain patents. 

Oxford Nanopore said it "does not believe BGI's nanopore-based sequencing technology is able to be used in commercial products around the world without infringing or misappropriating the group's substantial portfolio of proprietary rights."

Named CycloneSeq, BGI's nanopore sequencing technology was developed and recently unveiled by BGI Research, a unit of BGI Group.

As previously reported, BGI Group, formally named BGI Shenzhen, has established a new subsidiary called Hangzhou BGI Xufeng Technology that holds the IP related to CycloneSeq. Earlier this year, BGI Xufeng granted the exclusive rights to commercialize and distribute CycloneSeq globally to BGI Group-affiliate MGI Tech.

On Monday, MGI officially announced the launch of two nanopore sequencers based on the CycloneSeq technology: CycloneSeq-WT02 and CycloneSeq-WY01. According to MGI's website, CycloneSeq-WT02 can accommodate two flow cells that can run independently while CycloneSeq-WY01 operates one.

MGI said the CycloneSeq-WT02 sequencer will be open for order in select countries later this year through MGI's commercial channel while CycloneSeq-WY01 will become commercially available in the first half of 2025. MGI did not immediately respond to a request to comment on which countries the sequencers will be available in.

The impending lawsuit from Oxford Nanopore is likely to further hamper the BGI affiliates' attempts to penetrate Western markets. On Monday, the US Congress passed the Biosecure Act, which specifically targets Chinese biotech companies, including BGI Group, its affiliate MGI Tech, and MGI subsidiary Complete Genomics, aiming to cut off federal funding from these entities.

Oxford Nanopore, BGI Group, MGI Tech, and Complete Genomics declined to comment on the pending litigation.

[bamboo2] 10/9/2024 11:06

For info this is not the first time that ONT has experienced the possibility of litigation. There have been at least two cases with Pacb and another with Illumina. So far, ONT has always got the outcome it wanted. I guess there's no point having patents if they don't stand up in court.

BGI is not the only potential competition. Nanopore sequencers have been under development for some years elsewhere in the bio-tec world. In a way this potential competition is a good thing as it helps validate the idea that the tech is a worthwhile endeavour.

[brucie5] 10/9/2024 09:22

I don't think a company that exists by virtue its technology patents will be surprised to see infringements; these are inevitable and competitors will no doubt seek to test their resolve. It also presumably has to show its research partners that same willingness to defend their mutual interests.


Oxford Nanopore has an intellectual property portfolio of more than 2,600 issued patents and patent applications, in over 260 patent families. These cover all aspects of nanopore sensing including fundamental patents for nanopore sensing, and patents relating to DNA-sequencing.

Oxford Nanopore is developing a platform technology that may be adapted with a variety of nanopore sensors for the analysis of different molecules. The IP portfolio reflects the broad range of expertise and active R&D projects that are in progress at Oxford Nanopore and supported research within the laboratories of our academic collaborators. These projects include the development of nanopore DNA-sequencing technology, protein analysis, and the development of solid-state nanopores including graphene.

Between the Company’s foundation in 2005 and 2008, Oxford Nanopore established a range of exclusive licensing agreements and collaborations with the world’s leading researchers in Nanopore sensing. These included Oxford University Innovation, Harvard University, UMASS, Boston University, Texas A&M and University of California, Santa Cruz. The full range of agreements now includes Brown University, Cambridge University, Illinois University, Stanford University, VIB and Vrije Universiteit Brussel, KU Leuven, University College of London, University of Michigan, University of Massachusetts, The Ohio State University, Yissum R&D Company of the Hebrew University of Jerusalem and the University of Southampton.

[the big fella] 10/9/2024 09:13

But not something they want to devote time and money to.

[p1nkfish] 10/9/2024 08:33

No choice but to litigate, a strongly worded letter won't do it.
Shame about the distraction.
What difference it will make internal to China TBD, a law unto themselves.

It will help give Ox Nano ever more impetus to stay in front and put as much white water between themselves and fast followers - no bad thing.

[brucie5] 10/9/2024 06:27

This is surely inevitable and probably timely: so long as the Chinese seek to copy, ONT will need to litigate.

[bamboo2] 10/9/2024 06:14

The above refers to the commercial release of a Nanopore based sequencer by Chinese co. MGI.

Currently it looks unlikely that they will be able to supply the kit outside of China without breaking ONT's copyright.

MGI have recently capitalised on Illumina's ending of patents by copying much of their SBS tech and releasing sequencers that compete in the short read market.

The scientists I follow seem to be suggesting that performance of the MGI sequencer is running a few years behind that of ONT's.

[bamboo2] 10/9/2024 06:08

10 September 2024

Oxford Nanopore Technologies plc

Oxford Nanopore seeks discovery in connection with anticipated breach of contract action

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or "the Group"), the company delivering a new generation of nanopore-based molecular sensing technology, today announces that it has filed an ex parte application under 28 U.S.C. § 1782 in the U.S. District Court for the Northern District of California, for leave to serve subpoenas on Complete Genomics, Inc., Innomics Inc. (formerly known as BGI Americas Corp.), MGI Americas, Inc. ("MGI"), and others in support of a lawsuit that Oxford Nanopore intends to file in the courts of England and Wales.



Oxford Nanopore anticipates bringing claims against BGI Tech Solutions Co., Ltd, BGI Group, BGI, Beijing Genomics Institute at Shenzhen, MGI Holdings Co., Limited and MGI Tech Co., Ltd in England for, inter alia, claims for breach of contractual obligations, claims for breach of common law obligations of confidence, breach of duties under the Trade Secrets (enforcement etc.) Regulations 2018, and an entitlement claim to a license of certain patents. ̷9;



Additionally, while not commenting on future litigation, the Group does not believe BGI's nanopore-based sequencing technology is able to be used in commercial products around the World without infringing or misappropriating the Group's substantial portfolio of proprietary rights.

[eeza] 09/9/2024 19:12

It's the AT trades, on the book on SETS, that move the share price O trades move prices in MM controlled stocks depending on MM needs.

[bamboo2] 09/9/2024 18:04

Brucie, Possibly delayed trades or rollovers?

Trades of a certain size can be delayed from earlier in the day or week.
Rollovers I know nothing about, although they are often two trades close together totalling the same amount of shares. [others might know more]

[brucie5] 09/9/2024 16:41

Pleasant, if modest rise today of 1.48%. Would be nice to see rise above 1.50, which is the 6 month high; thereafter I make resistance points at 1.60 and £2.

Naive question: Can anyone explain to me why the ASK price remains at 144.7 when the last two (O)trades were for 42.6? I think I understand what an O trade is - but why does it not take the price down with it?

Asking for a friend, obvs..
;)


Date Time Trade Prc Volume Buy/Sell Bid Ask Value
09-Sep-24 16:38:04 142.637 42,610 Unknown* 144.30 144.70 60.78k O
09-Sep-24 16:38:04 142.708 42,610 Unknown* 144.30 144.70 60.81k

[brucie5] 09/9/2024 07:28

Thanks Keyno, always good to talk. Happy hunting.